Identification and Characterization of RK22, a Novel Antimicrobial Peptide from Hirudinaria manillensis against Methicillin Resistant Staphylococcus aureus
Lu X, Yang M, Zhou S, Yang S, Chen X, Khalid M, Wang K, Fang Y, Wang C, Lai R, Duan Z (2023) · International Journal of Molecular Sciences · n=0
Study Profile
- Design
- bioinformatic discovery and synthesis of a novel antimicrobial peptide (RK22) from Hirudinaria manillensis salivary-gland transcriptome, followed by in-vitro and in-vivo antimicrobial assays against methicillin-resistant Staphylococcus aureus (MRSA); Kunming Institute of Zoology, Chinese Academy of Sciences
- Sample size (n)
- —
- Intervention
- Synthetic RK22 peptide administered against MRSA in-vitro (MIC determination, biofilm assays) and in-vivo (mouse model)
- Comparator
- Untreated MRSA controls; comparator with LL-37 endogenous antimicrobial peptide
- Primary endpoint
- Antimicrobial activity (MIC), biofilm inhibition, in-vivo infection suppression, and safety (cytotoxicity, hemolysis, coagulation effects)
- Primary result
- RK22 showed potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strain; rapid bacterial killing; inhibited biofilm formation and promoted biofilm eradication; good plasma stability; negligible cytotoxicity; minimal hemolysis; no significant pro-coagulation effects; in-vivo administration significantly inhibited MRSA infection
- Follow-up duration
- In-vivo mouse experiments (days to weeks)
- PMID
- 37686259
Key Findings
- Novel RK22 antimicrobial peptide identified from H. manillensis salivary gland transcriptome
- Potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strains
- Biofilm inhibition and eradication — relevant to chronic-wound and indwelling-device infections
- Good safety profile (low cytotoxicity, minimal hemolysis, no pro-coagulation)
- In-vivo mouse efficacy demonstrated — supports advancing to GLP-toxicology and Phase-I evaluation
Limitations
- Preclinical (in-vitro + mouse) — no human data
- Mouse model does not capture all clinical complexity of MRSA disease
- Long-term toxicology, pharmacokinetics, and immunogenicity not characterized
- Resistance development potential not yet studied
- Hirudinaria manillensis is not the K040187-cleared device leech
Clinical Implications
Lu 2023 illustrates how underrepresented Asian medicinal-leech sialotranscriptomes can yield translational antimicrobial drug candidates with activity against MDR pathogens. For ASH, the study underscores that leech-pharmacology is a deep biodiversity reservoir extending beyond the established hirudin literature. No US K040187 clinical-practice implications; relevant to translational antimicrobial drug discovery.
Related Trials
Hirudins and hirudin-like factors in Hirudinidae: implications for function and phylogenetic relationships
Müller C, Haase M, Lemke S, Hildebrandt JP (2016)
Diversity of hirudin and hirudin-like factor genes in the North-African medicinal leech, Hirudo troctina
Ahmed RB, Abilov A, Müller C (2024)
Monomeric and Oligomeric Decorsins of the Asian Medicinal Leech
Tolksdorf C, Wolf R, Rauch BH, Jedlitschky G, Müller C (2025)
Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential
Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K (2026)